Back to Screener

20/20 Biolabs, Inc. - Common Stock (AIDX)

NASDAQ Nano Cap
$1.83
Market Cap: $19M
Data as of Dec 31, 2025

Investment Snapshot

  • Piotroski F-Score 4/9 — moderate financial health
  • Negative net margin (-182.8%) — currently unprofitable
  • Revenue growing at 17% annually

20/20 Biolabs, Inc. - Common Stock (AIDX) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $19 million . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .

Value Score

Key Metrics

P/E Ratio
EPS
$-0.36
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology.

20/20 Biolabs, Inc. - Common Stock — Fundamental Analysis Summary

StockPik's composite Value Score for AIDX is 42/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

AIDX reports a moderate gross margin of 29.6% and a negative operating margin of -162.9%.

AIDX shows revenue growing at 17% year-over-year, with earnings growing at 33%.

How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
AI
Next
AIFF